Breast cancer
A phase 3 clinical study conducted across multiple sites, an unpremeditated, unmasked trial, standard of care, side-by-side comparison study of Pyrotinib plus Capecitabine compared with Lapatinib plus Capecitabine in patients with HER2-positive advanced breast cancer.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Registry summary (technical)
A phase III, multicentre, randomized, open label, active controlled, parallel group, non-inferiority study of Pyrotinib plus Capecitabine compared with Lapatinib plus Capecitabine in patients with HER2-positive metastatic breast cancer - Nil
Sponsor: Syngene International Limited
CTRI/2025/09/094678 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 14 Sep 2026 · read by us 5 Nov 2026